Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc. develops and commercializes treatments for rare diseases, with a portfolio built around specialty pediatric and orphan-drug products. The company also advances a pipeline of late-stage product candidates and monetizes certain assets through out-licensing and milestone-based licensing revenue.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaApproved specialty medicines sold through pharmacy distributors and wholesalers for rare disease patients.
Revenue from out-licensing rights and sales-based royalties tied to partnered products and territories.
Product candidates in development that may become future commercial products or licensing assets.
Tuotteet
Raportoitu · osuus liikevaihdosta- Product Sales and Royalties95,9 %
- License4,1 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
Eton sells primarily to pharmacy distributor customers and wholesale pharmaceutical distributors, which then supply hospitals and other end users. Its products are used for rare disease treatment, so demand is concentrated in specialty channels and patient-specific fulfillment rather than broad retail pharmacy traffic.
Buy and store Eton's specialty products, then ship them to fulfill patient-specific orders.
Purchase product for resale to hospitals and other end users under purchase orders and master agreements.
Pay for rights outside the U.S. or generate sales-based royalties tied to partnered products.
Indirect buyers that receive product through wholesalers for rare-disease treatment use.
Strategia
Eton's strategy centers on growing its rare-disease franchise by expanding sales of existing commercial products and bringing late-stage candidates into the market. It is also using licensing and divestiture activity to monetize assets, while keeping development spending focused on programs such as ET-700 and ET-800.
The company depends on a small number of specialty products, so volume growth in existing brands is the fastest way to improve revenue.
New approvals or launches can diversify revenue and reduce concentration in the current portfolio.
Licensing revenue and milestone payments can fund operations without relying only on product sales.
Maantiede
Eton is a U.S.-based company and its commercial sales are primarily tied to the United States, where product is sold through domestic specialty distribution channels. The company also has international exposure through out-licensing of INCRELEX® rights outside the U.S., which adds non-U.S. licensing revenue and reduces reliance on the domestic market alone.
Riskit
Eton is exposed to concentration risk because its revenue base depends on a limited number of rare-disease products and specialty distribution channels. It also faces execution risk in development, commercialization, and reimbursement, while reserve estimates for chargebacks, rebates, returns, and discounts can materially affect reported revenue.
A few commercial products drive most revenue, so any demand disruption or competitive pressure can have an outsized effect.
Net revenue is reduced by chargebacks, Medicaid rebates, prompt-pay discounts, and returns estimates that require judgment.
Kohdistuu: Sales reserves and accrued liabilities
Late-stage candidates may face clinical, regulatory, manufacturing, or commercialization setbacks.
The company may need additional capital if development spend or working capital needs rise faster than expected.
Kirjanpito
Harkinnanvaraiset erätChargebacks, Medicaid rebates, prompt-payment discounts, and returns are estimated at sale and can materially change net revenue.
Vaikutus: Affects reported product sales and receivables
Revenue is recognized when wholesalers take title and control, so shipment timing affects quarterly results.
Vaikutus: Creates quarter-to-quarter volatility
Out-licensing and milestone events can create lumpy revenue recognition unrelated to product demand.
Vaikutus: Can materially affect quarterly revenue mix
Acquired product rights and related intangibles generate amortization expense and potential impairment risk.
Vaikutus: Affects operating income and non-GAAP reconciliation
Revalued inventory from acquisitions can create temporary cost of sales pressure.
Vaikutus: Can depress gross margin in the near term
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Ultragenyx Pharmaceutical Inc.
RARE · Pharmaceutical Preparations
Quoin Pharmaceuticals Ltd.
QNRX · Pharmaceutical Preparations
PTC Therapeutics, Inc
PTCT · Pharmaceutical Preparations
PTC Therapeutics is a U.S.-based global biopharmaceutical company focused on discovering, developing, and commercializing medicines for rare disorders.
Rigel Pharmaceuticals, Inc
RIGL · Pharmaceutical Preparations
Rigel Pharmaceuticals is a U.S.-based biotechnology company focused on therapies for hematologic disorders and cancer.
Stoke Therapeutics, Inc.
STOK · Pharmaceutical Preparations
Rocket Pharmaceuticals, Inc
RCKT · Pharmaceutical Preparations
Rocket Pharmaceuticals is a U.S.-based late-stage biotechnology company focused on developing genetic therapies for rare inherited diseases.
Päivitetty: 24.9.2026